Northrop Grumman is one of the week's stronger performers among large-cap defense names, up 3.3% Tuesday and 2.3% on the week to close at $589.14 — a move that has left at least one analyst target already looking stale just hours after it was raised.
The analyst angle is the most live tension right now. TD Cowen's Gautam Khanna lifted his target to $590 this morning — essentially spot price — while holding his Hold rating. The move follows a busy month of revisions: Citigroup raised to $667 last week with a Buy, and UBS bumped to $685 at end-July. On the other side, JP Morgan trimmed to $600 post-Q2 earnings, and Goldman Sachs cut to $533 in mid-July. The consensus mean target sits at $647, implying roughly 10% upside from current levels — respectable for a defense prime, but the dispersion between Goldman's $533 and UBS's $685 signals a genuinely split Street. Bulls point to long-duration programs — B-21, F/A-XX, Golden Dome — as multi-year revenue drivers into 2027 and beyond. Bears flag space segment softness from program realignments and a management posture that favors reinvestment over buybacks, which raises questions about near-term free cash flow conversion.
Valuation has drifted higher with the stock. The trailing P/E has expanded roughly 1.7 points over the past month to about 19.6x, and price-to-book has moved up by 0.38 to 4.2x. EV/EBITDA, at 14.8x, has actually eased slightly — a modest compression suggesting the market is giving credit for earnings growth rather than purely multiple expansion. The dividend score ranks in the 99th percentile of the ORTEX universe, reflecting consistent payouts, though the dividend data on file is stale so the current yield should be verified independently. EPS surprise ranks in the 75th percentile — the company has a reliable beat record.
Short positioning is a non-story here and should be treated as such. At 1.5% of free float, short interest has fallen nearly 9% on the week and over 10% in the past month. Shares available to borrow are essentially unlimited — the lending pool is so deep it hits ORTEX's ceiling reading — and the cost to borrow is a negligible 0.38%. The ORTEX short score has drifted steadily lower across August, from 30.7 to 30.1, consistent with shorts quietly covering into the rally. There is no squeeze dynamic, no borrow tightness, and no directional signal worth reading into from the short side. The options market is similarly unexcited: the put/call ratio at 1.10 is almost exactly its 20-day average, with a z-score of essentially zero. Options traders are neither hedging aggressively nor reaching for upside — positioning is neutral.
Among close peers, NOC outpaced RTX (+0.7% on the week) and LMT (+1.6%) over the same period, and widened the gap on LHX, which fell 2.3%. The outperformance narrows the year-to-date lag noted in prior coverage, though it doesn't erase it. Wellington Management added over 2.1 million shares as of end-June, making it the most notable institutional mover in the recent filing window — a significant incremental conviction bet from a large active manager.
The next scheduled catalyst is Q3 earnings on October 29. With the stock now trading essentially at TD Cowen's freshly raised Hold target and Goldman's $533 target now more than 10% below the current price, the Q3 print will determine whether the bulls' program-execution confidence or the bears' free-cash-flow caution proves better founded.
See the live data behind this article on ORTEX.
Open NOC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
